PETREMAC was an open-label, phase 2, multi-center trial allocating patients with large (>4 cm diameter±node metastases) breast tumors to different treatment arms based on estrogen receptor (ER)/progesterone receptor (PGR) and HER2 expression and TP53 tumor mutation status [13]. This evidence concerns the gene ESR1 and neoplasm.